Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
Second publication of MAR001 preclinical results in eBioMedicine that demonstrate improved plasma lipid profiles
SOUTH SAN FRANCISCO, Calif., May 16, 2025--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that positive results from a Phase 2a clinical trial of MAR001 were published in The Lancet entitled "Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies." The publication follows a recent late-breaking oral presentation of the Phase 2a results at the 93rd EAS Congress and can be accessed here. In addition, Marea announced a publication of MAR001 preclinical results in the peer-reviewed journal eBioMedicine entitled "A Novel ANGPTL4 Inhibitory Antibody Safely Improves Lipid Profiles in Non-Human Primates." The publication can be accessed here.
MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. Results from Marea's Phase 2a clinical trial of MAR001 demonstrated approximately 53% placebo-adjusted mean reductions in remnant cholesterol and triglycerides at 12 weeks with a favorable safety profile.
"We are excited to have our MAR001 Phase 2a clinical results and preclinical data recognized within the broader scientific community through these publications in The Lancet and eBioMedicine," said Ethan Weiss, M.D., chief scientific officer of Marea. "These findings validate ANGPTL4 inhibition and the ability of MAR001 to safely and effectively reduce remnant cholesterol and triglycerides, which align with genetic findings and support further development in addressing atherosclerotic cardiovascular disease risk. We look forward to initiating a Phase 2b trial of MAR001 in the second quarter of 2025."
About Remnant Cholesterol
Remnant cholesterol is carried by triglyceride-rich lipoproteins, is highly atherogenic, and drives cardiovascular events independent of classical risk factors like LDL cholesterol, diabetes, or obesity. There are currently no available targeted therapies to lower remnant cholesterol and improve metabolic function.
About MAR001
MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby augmenting lipoprotein lipase (LPL) activity, MAR001 is designed to lower remnant cholesterol and improve adipose tissue function. Human genetic data has identified ANGPTL4 as a highly promising therapeutic target because loss of function alleles lead to lower remnant cholesterol, improved adipose distribution, improved insulin sensitivity, lower triglyceride levels, and protection from cardiovascular disease and type 2 diabetes.
MAR001 is being developed to reduce the risk of major adverse cardiovascular events (MACE) in adults with established atherosclerotic cardiovascular disease (ASCVD) plus elevated triglycerides and remnant cholesterol.
Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. Results from a Phase 2a study of MAR001 demonstrated clinically meaningful reductions in remnant cholesterol and triglycerides. Marea plans to advance MAR001 into Phase 2b clinical development in the second quarter of 2025.
About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company's lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250516110509/en/
Contacts
Media Contact:Katie Engleman, 1ABkatie@1abmedia.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
5 days ago
- Forbes
The Prototype: AI Tools May Degrade Doctors' Skills
In this week's edition of The Prototype, we look at the risk of depending on AI to 'think' for you, mass-producing satellites, a startup helping NASA avoid space junk, and more. To get The Prototype in your inbox, sign up here . A study published this week in The Lancet examined the impact of an AI tool for colonoscopies on the skills of doctors. The researchers tested doctors' abilities to find certain abnormalities in patients for three months before using AI, then tested them again after they'd used the tool for three months. They found that doctors' ability to spot those abnormalities on their own degraded after using AI. And while that might not be a big deal a few decades down the road when AI-assisted detections are the norm, it does pose a problem right now, because these tools aren't universal. A doctor accustomed to using AI at one hospital might find their performance declines working at a hospital that hasn't adopted it yet. It also raises larger questions about letting AI do your 'thinking' for you, because what's lost might be more than one particular skill. Studies have shown, for example, that overreliance on GPS for driving could degrade your spatial memory. As we enter a brave new world of AI, it will be increasingly important to not only know how to use it, but also when not to use it. Stay tuned. Apex Wants To Bring Henry Ford-Style Mass Production To Satellites S atellite manufacturing has long been a bespoke business with spacecraft customized for the missions they are sent on. Elevated costs and delays come with the territory. With more and more small satellites being launched into low-Earth orbit, Lost Angeles-based Apex has developed standardized spacecraft it says are a faster and more affordable option. The company is marketing three standardized satellite bodies with power and control systems that can be quickly customized by clients with sensors and payloads. Like, say, weapons to shoot down intercontinental ballistic missiles, as envisioned for President Trump's Golden Dome. Similar to automakers, Apex offers different versions of its satellites, with options like more power, a fancier communications system and a choice between electrical or chemical propulsion. 'You either take it or you leave it,' CEO Ian Cinnamon said. Read the whole story at Forbes . DISCOVERY OF THE WEEK: DEVICE LETS USERS COMMUNICATE WITH THOUGHTS Neurological disorders like ALS can make it difficult for people to communicate. And while there are devices that can help them speak, they're often much slower than the speech that people take for granted. A team of researchers have invented a new device that may change this: a computer device implanted in the brain that can pick up the neural activity associated with speech-based thinking and translate it into words. The technology is still in its infancy, but opens the door to brain-computer interfaces that may one day give patients the ability to communicate as quickly as they think. FINAL FRONTIER: LEOLABS WANTS TO HELP NASA AVOID SPACE JUNK Menlo Park, Calif.-based space startup LeoLabs has entered into an agreement for NASA to evaluate its data for use in evaluating the risk of satellite and spacecraft collisions. The goal would be to integrate LeoLabs' data, which is collected by multiple radar systems around the world, with the Air Force radar systems that NASA currently uses to track objects in space. (To learn more about LeoLabs, check out a story I wrote about the company a few years back.) FORBES CALLED IT: HELPING DOGS LIVE LONGER Every year, Forbes selects 25 VC-backed companies for our Next Billion-Dollar Startups List, highlighting those whose growth puts them on track to become worth $1 billion or more. Making the list this year is biotech startup Loyal, which is developing pills that could extend dogs' lifespans. The company is currently testing its medication on several hundred canines in a clinical trial, with hopes of bringing it to market soon. We've had our eye on Loyal for a few years now: its founder, Celine Halioua, is an alumna of our 30 Under 30 list, and I wrote about her company's progress a couple of years ago. If Loyal is successful in extending the life of dogs, its next goal will be even more ambitious: extending ours. 'I think the general public will be blown away when they realize they can go to the vet and get a drug to extend their dogs' lifespan,' Halioua told my colleague Amy Feldman. 'Then they'll ask, 'Why can't I do this for my grandma?'' WHAT ELSE I WROTE THIS WEEK Earlier this week, I wrote about biotech startup Tahoe Therapeutics, which just raised $30 million in investment to support scaling up its dataset of how different molecules interact with living cells. Their goal? To train AI models to simulate cells as a way to accelerate the discovery of new medicines. Right now, data is the limiting factor in training AI, but recently the company released a dataset with 100 million cellular datapoints to improve those models. In my other newsletter, InnovationRx, Amy Feldman and I looked at how misinformation about vaccines led to the recent shooting at the CDC, a company building programmable mRNA to fight cancer, Robert F. Kennedy Jr.'s fight with a medical journal, and more. SCIENCE AND TECH TIDBITS The federal government has pulled funds for California's high-speed rail, but the project may have an unlikely savior: AI data centers. Google is teaming up with pollster Scott Rasmussen for a project that would use AI to produce better political polling outcomes. Researchers at Texas A&M have developed a new carbon-fiber material that can heal itself when broken and is harder than steel. Scientists have developed a 'skin in a syringe'—a gel that contains living skin cells–that can be 3D printed into a skin graft and applied to a wound, enabling burns to heal without leaving scars. PRO SCIENCE TIP: THINK OUTSIDE THE SEARCH ENGINE Have you ever fired up Google during a brainstorming session to help your teammates generate ideas? You might think twice about doing so again. A recent study explored how creativity varies between groups when one has access to the internet and one doesn't. 244 people were divided into small groups with half of them given access to a search engine. The groups were tasked with coming up with as many ideas as possible for using a particular object. One object didn't have many results on Google when searching; the other had many. The researchers found that those who didn't use Google tended to come up with more creative and effective ideas than those who did. What's more, when there were a lot of Google search results, the groups tended to converge on the top answers given rather than coming up with their own creative responses. WHAT'S ENTERTAINING ME THIS WEEK I'm a few episodes into the new season of King of the Hill , the first since it was cancelled in 2010. The show's creators chose to advance the series in time a little bit, meaning that we get to see Hank and Peggy Hill struggling to navigate retirement while their son navigates early adulthood. If you're a fan of the original iteration, you won't be disappointed by the new episodes. And my favorite touch? In the year 2025, resident conspiracy theorist character Dale Gribble doesn't have his craziest ideas ignored anymore. Instead, he's got a Substack and a bunch of willing subscribers. MORE FROM FORBES Forbes Meet The Mastermind Behind The $1.9 Billion Poppi Deal By Chloe Sorvino Forbes As Trump Rolls Back Federal Financial Regulation, Blue State Regulators Step Up By Jeff Kauflin Forbes Why Paramount's $7.7 Billion UFC Gamble Will Pay Off By Matt Craig
Business Insider
6 days ago
- Business Insider
Akero Therapeutics' efruxifermin shows efficacy in Phase 2b MASH, fibrosis trial
Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis – MASH – and moderate or advanced fibrosis. Continued treatment with EFX from 24 to 96 weeks resulted in more participants exhibiting improvements in fibrosis and MASH, such that there was near complete reversal of disease in almost one-third of participants treated with the 50mg dose of EFX. In the modified intent-to-treat population at week 96, 49% of participants who received 50mg EFX achieved at least one stage fibrosis improvement without worsening of MASH evaluated by liver histology – the primary endpoint -, vs. 19% for placebo. The secondary endpoint of MASH resolution without fibrosis worsening was achieved by 40% of participants receiving 28mg EFX and 37% receiving 50mg EFX in the mITT population at week 96, vs. 19% for placebo. A composite endpoint of both MASH resolution and greater than or equal to1-stage fibrosis improvement was met by 35% and 28% of participants in the 50mg and 28mg EFX treatment groups, respectively, vs. 7% for placebo. EFX was generally well tolerated, with a safety profile consistent with previous trials. Confirmation of these potential benefits of EFX is being evaluated in the ongoing Phase 3 SYNCHRONY clinical trial program. Elevate Your Investing Strategy:
The Verge
13-08-2025
- The Verge
Some doctors got worse at detecting cancer after relying on AI
We've heard about upskilling and re-skilling due to AI — but how about de-skilling? A new study published this week found that doctors who frequently use AI to detect cancer in one medical procedure got significantly worse at doing so. The researchers set out to discover whether continuous exposure to AI impacted doctors' behavior when conducting colonoscopy, so they decided to assess 'how endoscopists who regularly used AI performed colonoscopy when AI was not in use.' The answer: Not so hot. The rate was about six percentage points lower. The study was published in The Lancet Gastroenterology & Hepatology journal by medical professionals and researchers in countries including Poland, Norway, Sweden, the U.K., and Japan. It followed doctors at four endoscopy centers in Poland, which were part of a trial program focusing on AI's use in colonoscopy for potential cancer prevention. It raises questions about the use of AI in healthcare, when it helps and when it could hurt. Last week, The Verge reported on a Google healthcare AI model's instance of potentially hallucinating a body part and where medical professionals think the industry will go from from this author will be added to your daily email digest and your homepage feed. See All by Hayden Field Posts from this topic will be added to your daily email digest and your homepage feed. See All AI Posts from this topic will be added to your daily email digest and your homepage feed. See All Health Posts from this topic will be added to your daily email digest and your homepage feed. See All News Posts from this topic will be added to your daily email digest and your homepage feed. See All Science
